
Urogen Pharma (URGN) Stock
Specialty drug company developing treatments for urinary cancers. Here's the price, business snapshot, and what's worth knowing about Urogen Pharma in November 2026.
UroGen Pharma Ltd (URGN) is a speciality biopharmaceutical company focused on urology and uro-oncology. The business develops treatments using a local drug‑delivery platform designed to retain therapeutic agents in the urinary tract, and it commercialises products for rare or difficult-to-treat urological cancers. With a market capitalisation around $839m, UroGen sits in the small‑to‑mid cap biotech space where clinical progress, regulatory decisions and early commercial traction drive value. Investors should note the typical biotech profile: potential for significant upside if clinical and commercial milestones are met, but also meaningful risks including trial setbacks, regulatory uncertainty, reimbursement challenges and share dilution from future fundraising. Performance can be volatile and past performance is not a reliable indicator of future results. This summary is educational and not personal financial advice; suitability depends on your circumstances and you should consult a financial professional before investing.
Urogen Pharma (URGN) Stock Forecast
Analyst price target, next 12 months
$53.83
+92.1% vs today's $28.03
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Urogen Pharma have a consensus 12-month target of $53.83, above the current price of $28.03.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Urogen Pharma's stock with a target price of $53.83, indicating strong growth potential.
Financial Health
UROGEN Pharma is performing well with strong revenue, impressive profit margins, and solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Commercial momentum
JELMYTO and other commercial activities can drive revenue growth if adoption and reimbursement progress; revenue can be uneven and is subject to payer decisions.
Platform potential
The local delivery platform aims to improve drug retention in the urinary tract, which may offer clinical advantages; clinical validation and uptake remain key uncertainties.
Regulatory pathway
Approvals, label expansions and international reimbursement shape long-term prospects, though regulatory and market hurdles can create volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.